In 2001, imatinib, the first-in-class tyrosine kinase inhibitor (TKI), was approved by the Food and Drug Administration (FDA) for treatment of mutated BCR-ABL (breakpoint cluster region (BCR) and abelson murine leukemia viral oncogene homolog 1 (ABL1)) chronic myeloid leukemia (CML) [28, 29]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.